Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and 'novel agent' therapy

Torti Lorenza; Pulini Stefano; Morelli Anna Maria; Bacci Francesco; Di Bartolomeo Paolo

首页> 外文期刊>International journal of hematology >Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and 'novel agent' therapy

【24h】

Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and 'novel agent' therapy

机译：高剂量和“新药”治疗时代复发和过度治疗的多发性骨髓瘤的内脏利什曼病

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International journal of hematology》 |2015年第4期|共3页
作者
Torti Lorenza; Pulini Stefano; Morelli Anna Maria; Bacci Francesco; Di Bartolomeo Paolo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词
Immunodeficiency; Multiple myeloma; Novel agents; Opportunistic infections; Leishmaniasis;

机译：免疫功能低下;多发性骨髓瘤;新型药物;机会性感染;利什曼病;

相似文献

外文文献
中文文献
专利

1. Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and "novel agent" therapy [J] . Torti Lorenza, Pulini Stefano, Morelli Anna Maria, International journal of hematology . 2015,第4期

机译：高剂量和“新药”治疗时代复发和过度治疗的多发性骨髓瘤的内脏利什曼病
2. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): A randomised, open-label, phase 3 trial [J] . CookG., WilliamsC., BrownJ.M., The lancet oncology . 2014,第8期

机译：大剂量化疗加自体干细胞移植作为巩固疗法治疗先前自体干细胞移植后复发的多发性骨髓瘤患者（NCRI骨髓瘤X复发[强化试验]）：一项随机，开放标签的3期试验
3. Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma [J] . R Fenk, B Hoyer, U Steidl, Leukemia . 2005,第1期

机译：单药沙利度胺治疗多发性骨髓瘤患者大剂量化疗后的首次复发
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. Cost-Effectiveness of Oral Agents in Relapsing-Remitting Multiple Sclerosis Compared to Interferon-Based Therapy in Saudi Arabia [D] . Alskaabi, May. 2017

机译：沙特阿拉伯口服药物在复发缓解型多发性硬化症中的成本效果与基于干扰素的疗法相比
6. Correspondence: High-risk myeloma: a gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [O] . Fenghuang Zhan, Bart Barlogie, George Mulligan, -1

机译：对应：高危骨髓瘤：采用高剂量治疗的新诊断多发性骨髓瘤的基于基因表达的风险分层模型可预测用单药硼替佐米或大剂量地塞米松治疗的复发性疾病的预后
7. High-risk myeloma: a gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [O] . Zhan, Fenghuang, Barlogie, Bart, Mulligan, George, 2008

机译：高危骨髓瘤：采用高剂量治疗的新诊断多发性骨髓瘤的基于基因表达的风险分层模型可预测用单药硼替佐米或高剂量地塞米松治疗的复发性疾病的预后

Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and 'novel agent' therapy

著录项

相似文献

相关主题

期刊订阅